Lynovex

Lynovex® (NM001) is a first-in-class orphan drug candidate for cystic fibrosis.

NovaBiotics recognises more treatments, and better treatments, are desperately needed to address these symptoms.

Our solution is Lynovex® (NM001), which is being developed to improve the quality & length of life of all CF patients – not just those with particular CFTR genotypes.

See the effect of Lynovex on cystic fibrosis sputum

What Is Lynovex?
The Story So Far
Clinical Studies
Lynovex® Latest

Lynovex® Latest

Data On The Mucolytic Mechanism Of Action Of Lynovex Will Be Presented At Nacfc 2018.

Care Cf 1 Lynovex Clinical Trial Data Selected For Presentation At Nacfc 2018.

Lynovex Oral meets study objectives for CARE CF 1 Clinical Trial

Cysteamine, An Endogenous Aminothiol, And Cystamine, The Disulfide Product Of Oxidation, Increase Pseudomonas Aeruginosa Sensitivity To Reactive Oxygen And Nitrogen Species And Potentiate Therapeutic Antibiotics Against Bacterial Infection.

How Lynovex Works To Boost Antibiotics In Combatting Pseudomonas Aeruginosa Infection In Cystic Fibrosis